US equities
|
NVDA
$239.11
▲+2.21%
SPCX
$168.12
▲+5.76%
MU
$1,059.38
▼-1.44%
TSLA
$380.51
▲+2.68%
MSFT
$527.09
▲+1.85%
SNDK
$1,690.75
▼-1.70%
INTC
$116.47
▼-2.40%
META
$742.73
▲+2.01%
NVDA
$239.11
▲+2.21%
SPCX
$168.12
▲+5.76%
MU
$1,059.38
▼-1.44%
TSLA
$380.51
▲+2.68%
MSFT
$527.09
▲+1.85%
SNDK
$1,690.75
▼-1.70%
INTC
$116.47
▼-2.40%
META
$742.73
▲+2.01%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
42.34
+0.94 (+2.27%)
Delayed Quote
Updated: 2:55 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 22, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 21, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
June 20, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 19, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 18, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
June 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm
June 16, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses
June 16, 2025
Via
ACCESS Newswire
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
↗
June 16, 2025
Via
Benzinga
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd. Investors of Upcoming Deadline
June 16, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert
↗
June 16, 2025
U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.
Via
Benzinga
Topics
Stocks
UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri
↗
June 16, 2025
UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.
Via
Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
June 15, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week
↗
June 13, 2025
UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.
Via
Benzinga
Top movers in Friday's session
↗
June 13, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer
↗
June 13, 2025
FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.
Via
Benzinga
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
↗
June 13, 2025
Via
Benzinga
UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20
↗
June 13, 2025
The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.
Via
Stocktwits
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
June 12, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Here are the top movers in Thursday's session.
↗
June 12, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
June 12, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
June 10, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
June 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against UroGen, Strategy Incorporated, and Organon and Encourages Investors to Contact the Firm
June 09, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – URGN
June 09, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd. Investors of Upcoming Deadline
June 09, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.
June 06, 2025
From
Robbins LLP
Via
GlobeNewswire
Which stocks are moving on Friday?
↗
June 06, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
June 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – URGN
June 06, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
